Since their emergence, mRNA vaccines have carried a quiet contradiction: the same nanoparticles that protect and deliver genetic instructions are drawn instinctively to the liver, an organ that neither needs nor benefits from the encounter. Researchers in Kawasaki, Japan have now addressed this with geometric precision — coating the liver's sinusoid walls with a temporary, biocompatible agent that redirects nanoparticles toward their intended destinations. The work, published in ACS Nano in August 2026, does not reinvent the vaccine; it clears the path the vaccine was always meant to travel.
Researchers develop coating to prevent mRNA nanoparticles from accumulating in liver
Cases of hepatitis following mRNA vaccination have been reported in humans due to unintended liver protein expression, which this method aims to prevent.
The liver is not where you want mRNA expressing proteins.
Mark
Why does the liver capture these nanoparticles in the first place? Is it bad luck, or is the liver actually doing what it's designed to do?
Mimi
The liver is doing exactly what it evolved to do—filter the bloodstream and trap foreign particles. Nanoparticles are small enough and lipid-based enough that the liver's filtering cells grab them naturally. It's not a flaw in the nanoparticles; it's a feature of the liver.
Mark
So the coating doesn't change the nanoparticles themselves. It changes the liver's ability to catch them.
Mimi
Precisely. The coating sits on the sinusoid walls like a temporary shield. It's not permanent—it washes away in hours. But during those hours, the nanoparticles slip past and reach the spleen instead.
Mark
And the spleen is where you want them for vaccines.
Mimi
For vaccines and cancer immunotherapies, yes. The spleen is where immune cells gather and train. If the nanoparticles reach the spleen, the immune response is stronger and more targeted. If they're trapped in the liver, you get either liver damage or immune tolerance—the liver essentially tells the immune system to ignore what it's seeing.
Mark
This coating agent—they're not inventing it from scratch.
Mimi
No. It's already in human trials for a different purpose entirely. That's what makes this practical. They're not asking regulators to approve something new. They're asking to use something already deemed safe in a different way.
Mark
How long does the protection last?
Mimi
A few hours. Just long enough for the nanoparticles to get where they need to go before the coating dissolves and the liver returns to normal function. It's elegant because it's temporary.
Le Pouls
- mRNA nanoparticles accumulate in the liver by default, causing liver cells to produce unintended proteins that the immune system sometimes attacks — documented hepatitis cases in vaccinated patients are the human cost of this design flaw.
- For cancer immunotherapies, the stakes are even higher: cytokines produced in the liver spill systemically, generating dangerous side effects, while every nanoparticle lost to the liver is one that never reaches the spleen or tumor site.
- A team led by Kazunori Kataoka engineered a PEG-based coating agent that temporarily lines liver sinusoid walls, physically blocking nanoparticle entry for a few hours before the body safely excretes it.
- In mice, the intervention reduced hepatic protein expression by dozens of times while multiplying spleen expression several-fold — gains that held across infectious disease vaccines, cancer vaccines, and cytokine therapies.
- Crucially, the coating agent is already in human clinical trials for a separate application, meaning its safety profile exists and the path to broader human use is shorter than for most experimental compounds.
Since their emergence, mRNA vaccines have carried a quiet contradiction: the same nanoparticles that protect and deliver genetic instructions are drawn instinctively to the liver, an organ that neither needs nor benefits from the encounter. Researchers in Kawasaki, Japan have now addressed this with geometric precision — coating the liver's sinusoid walls with a temporary, biocompatible agent that redirects nanoparticles toward their intended destinations. The work, published in ACS Nano in August 2026, does not reinvent the vaccine; it clears the path the vaccine was always meant to travel.
When mRNA vaccines arrived, they solved one crisis and quietly introduced another. The lipid nanoparticles that carry genetic instructions are effective — but they accumulate in the liver the way water finds the lowest point. Liver cells then produce proteins the immune system was never meant to encounter there, sometimes triggering hepatitis. For cancer therapies, the consequences extend further: cytokines manufactured in the liver flood the bloodstream systemwide, and every nanoparticle captured by the liver is one that never reaches the spleen or a tumor site.
Researchers at the Innovation Center of NanoMedicine in Kawasaki, Japan, led by Kazunori Kataoka, approached the problem architecturally. The liver's sinusoids — the capillaries where nanoparticles enter hepatic tissue — became the intervention point. The team built a coating agent from positively charged peptides attached to two chains of polyethylene glycol, a polymer with an established human safety record. Applied before nanoparticle injection, the coating temporarily shields sinusoid walls, then is excreted within hours, leaving no lasting trace in the liver.
The results in mice were decisive. Liver protein expression fell by several dozen times; spleen expression rose several-fold. Tested across three clinical scenarios — an infectious disease vaccine, a cancer vaccine, and cytokine therapy — the coating consistently suppressed unwanted hepatic activity while preserving or enhancing the immune responses that make these treatments work.
What accelerates the promise of this finding is that the coating agent is not a new unknown. It is already in human clinical trials for delivering oligonucleotide drugs to cancer sites, and its safety profile is established. Published in ACS Nano in August 2026, the research offers a near-term path to protecting patients from one of the most persistent unintended consequences of the mRNA medicine revolution.
When mRNA vaccines arrived, they solved one crisis and created another. The tiny lipid nanoparticles that ferry genetic instructions into the body work brilliantly—they protect the mRNA from being shredded by enzymes, slip past cellular barriers, and trigger immune responses that save lives. But they have a problem no one quite solved: they accumulate in the liver like water finding the lowest point.
This matters because the liver is not where you want mRNA expressing proteins. When a COVID vaccine is injected into muscle, some of those nanoparticles leak into the bloodstream and end up in the liver anyway, where they instruct liver cells to manufacture spike proteins. The immune system, seeing foreign proteins in the liver, sometimes attacks the organ itself—hepatitis cases have been documented after vaccination. At the same time, the liver's natural tendency to suppress immune responses can weaken the vaccine's effectiveness. For cancer therapies, the problem is worse: cytokine molecules produced in the liver spill into the bloodstream systemwide, causing dangerous side effects. And for any therapy targeting the spleen, every nanoparticle trapped in the liver is one that never reaches its intended destination.
Researchers at the Innovation Center of NanoMedicine in Kawasaki, Japan, led by Kazunori Kataoka, approached the problem geometrically. The liver's sinusoids—the capillaries that filter blood—are where nanoparticles enter hepatic tissue. What if you coated those walls? The team designed a coating agent made of positively charged peptides attached to two chains of polyethylene glycol, a polymer already used safely in human medicine. The coating sticks to sinusoid walls for only a few hours before the body excretes it, so there is no risk of long-term liver damage. And because it targets only the sinusoids, it leaves other organs untouched.
In mice, the results were striking. When researchers administered the coating agent before injecting mRNA nanoparticles intravenously, liver accumulation dropped dramatically. Protein expression in the liver fell by several dozen times. Meanwhile, protein expression in the spleen—where you want it—increased several-fold. The team then tested the coating in three clinical scenarios currently advancing through human trials. For an infectious disease vaccine modeled on COVID spike protein, the coating suppressed unwanted liver protein production while maintaining antibody responses and actually enhancing the cellular immunity that makes vaccines work. For cancer vaccines delivered intravenously, the coating boosted the cellular immune response essential for attacking tumors. For cytokine therapy, it prevented systemic cytokine distribution without sacrificing therapeutic effect.
What makes this work clinically viable is that the coating agent itself has already been tested in humans. It is currently in clinical trials for delivering oligonucleotide drugs to cancer sites, and its safety profile is established. This is not a theoretical advance requiring years of safety validation. The researchers published their findings in ACS Nano in August 2026, and the pathway to human trials appears clear. For the thousands of patients enrolled in mRNA vaccine and immunotherapy studies worldwide, this coating could mean the difference between a therapy that works and one that works while damaging the organ meant to filter your blood.
Citations marquantes
Cases of hepatitis following mRNA vaccination have been reported in humans due to unintended liver protein expression— Research findings from Innovation Center of NanoMedicine
Envie de l'histoire complète ?
Lire l'original sur EurekAlert! ↗
Science & Space